NCT00001131View on ClinicalTrials.gov

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
HIV Infections
Interventions
DRUG

Aldesleukin

Subcutaneous injection of IL-2 in the amount of 2.0 X 10\^6 mIU per day for the entire duration of therapy

DRUG

HAART

Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met

Trial Locations (1)

21205

Johns Hopkins Hosp, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001131 - Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients | Biotech Hunter | Biotech Hunter